Trading Report: The Core Laboratories NV (CLB) to Release Quarterly Earnings on Thursday

The Core Laboratories NV (CLB) to Release Quarterly Earnings on Thursday

Core Laboratories NV (NYSE:CLB) is scheduled to be issuing its Q316 quarterly earnings data on Thursday, October 20th.

Core Laboratories NV (NYSE:CLB) opened at 110.59 on Tuesday. The company’s 50-day moving average price is $110.44 and its 200 day moving average price is $117.52. The stock has a market capitalization of $4.88 billion, a P/E ratio of 58.67 and a beta of 1.45. Core Laboratories NV has a 52-week low of $84.50 and a 52-week high of $135.49.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, November 22nd. Stockholders of record on Friday, October 21st will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.99%. The ex-dividend date is Wednesday, October 19th. Core Laboratories NV’s dividend payout ratio is presently 117.65%.

Hedge funds have recently made changes to their positions in the company. Pinkerton Retirement Specialists LLC bought a new stake in shares of Core Laboratories NV during the second quarter worth $127,000. Fifth Third Bancorp boosted its stake in shares of Core Laboratories NV by 15.3% in the second quarter. Fifth Third Bancorp now owns 1,166 shares of the company’s stock worth $144,000 after buying an additional 155 shares in the last quarter. AXA boosted its stake in shares of Core Laboratories NV by 94.2% in the second quarter. AXA now owns 1,400 shares of the company’s stock worth $173,000 after buying an additional 679 shares in the last quarter. Loomis Sayles & Co. L P boosted its stake in shares of Core Laboratories NV by 78.9% in the second quarter. Loomis Sayles & Co. L P now owns 1,463 shares of the company’s stock worth $182,000 after buying an additional 645 shares in the last quarter. Finally, Johnson Investment Counsel Inc. bought a new stake in shares of Core Laboratories NV during the second quarter worth $207,000.

A number of analysts have recently commented on CLB shares. JPMorgan Chase & Co. reissued a “buy” rating on shares of Core Laboratories NV in a research note on Thursday, June 30th. Zacks Investment Research raised Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price objective on the stock in a research note on Wednesday, July 20th. Citigroup Inc. dropped their price objective on Core Laboratories NV from $123.00 to $118.00 and set a “neutral” rating on the stock in a research note on Monday, July 25th. Credit Suisse Group AG started coverage on Core Laboratories NV in a research note on Thursday, September 1st. They issued a “neutral” rating and a $115.00 price objective on the stock. Finally, Loop Capital started coverage on Core Laboratories NV in a research note on Friday, September 30th. They issued a “hold” rating and a $120.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $121.61.

Core Laboratories NV Company Profile

Related posts

Leave a Comment